{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.41","upperLimit":"1.58","value":"1.48"},{"groupId":"OG001","lowerLimit":"1.41","upperLimit":"2.63","value":"1.45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Time to response was defined as the time from first dose to first radiographic evidence of response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Encorafenib + cetuximab. Encorafenib: Orally, once daily. Cetuximab: Standard of care.","id":"OG000","title":"Phase 3: Doublet Arm"},{"description":"Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab. Cetuximab: Standard of care. Irinotecan: Standard of care. Folinic Acid: Standard of care. 5-Fluorouracil: Standard of care. Following protocol amendment, eligible participants could crossover to receive either triplet or doublet regimen.","id":"OG001","title":"Phase 3:Control Arm"}],"paramType":"MEDIAN","populationDescription":"The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 participants. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose to first radiographic evidence of response (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)","title":"(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per BICR","type":"SECONDARY","unitOfMeasure":"Months"}